Most Read Articles

Estimating the effect size of the 15Q11.2 BP1–BP2 deletion and its contribution to neurodevelopmental symptoms: recommendations for practice

Aia Elise Jønch, Elise Douard, Clara Moreau, Anke Van Dijck, Marzia Passeggeri, Frank Kooy, Jacques Puechberty, Carolyn Campbell, Damien Sanlaville, Henrietta Lefroy, Sonia Richetin, Aurelie Pain, David Geneviève, Usha Kini, Cédric Le Caignec, James Lespinasse, Anne-Bine Skytte, Bertrand Isidor, Christiane Zweier, Jean-Hubert Caberg, Marie-Ange Delrue, Rikke Steensbjerre Møller, Anders Bojesen, Helle Hjalgrim, Charlotte Brasch-Andersen, Emmanuelle Lemyre, Lilian Bomme Ousager, Sébastien Jacquemont, on behalf of 15q11.2 Working Group, Joris Andrieux, Angela Barnicoat, Patricia Blanchet, Sophie Blesson, Florence Niel Bütschi, Philippe M Campeau, Nora Chelloug, François-Guillaume Debray, Florence Fellmann, Alessandra Ferrarini, Richard Gibbons, Pernille Axel Gregersen, Juliane Hoyer, Ulrike Hüffmeier, Ditte Kjelgaard, Mandy Krumbiegel, Sébastien Lebon, Gaetan Lesca, Stéphanie Marignier, Sandra Mercier, Jacques Michaud, Grant Mitchell, Isabelle Mortemousque, Rikke S Møller, Mathilde Nizon, Genevieve Pierquin, Kristina Pilekær Sørensen, Sue Price, Pascal H Pujol, Vincent Ramaekers, Martine Raynaud, André Reis, Massimiliano Rossi, Pierre Sarda, Franco Stanzial, Helen Stewart, Dea Svaneby, Christian T Theil, Marianne Till, Yannis Trakadis, Dorothée Ville, Sandrine Vonwill, Andrew Wilkie, Antje Wiessner

10.1136/jmedgenet-2018-105879

August 26, 2019